Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 7/20 | 0.40 |
| ▸ | CDK8 | P49336 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700088 | 0.97 | OPRD1 (0.43) | OPRD1KCNH2CCNCCDK8LMNA | |
| SCHEMBL6701991 | 0.91 | OPRD1 (0.47) | OPRD1CCNCCDK8 | |
| SCHEMBL6701774 | 0.90 | KDM4E (0.47) | OPRD1KCNH2CCNCCDK8MAPT | |
| SCHEMBL6701730 | 0.84 | KMT2A (0.48) | OPRD1CCNCCDK8MAPTLMNA | |
| SCHEMBL6698658 | 0.82 | KMT2A (0.50) | OPRD1CCNCCDK8GAAMAPT | |
| SCHEMBL6701834 | 0.81 | TSHR (0.47) | OPRD1CCNCCDK8MAPTLMNA | |
| SCHEMBL6689954 | 0.80 | MAPT (0.49) | OPRD1GAAMAPTLMNATP53 | |
| SCHEMBL6700551 | 0.79 | HTT (0.52) | OPRD1GAAMAPTNPSR1TSHR | |
| SCHEMBL6690090 | 0.79 | OPRD1 (0.43) | OPRD1KCNH2USP2CYP1A2CYP3A4 | |
| SCHEMBL6696335 | 0.78 | ALDH1A1 (0.49) | OPRD1GAAMAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | OPRD1 1606/4885KCNH2 2756/4885CCNC 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.